相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Conformational Transition Pathways and Hidden Intermediates in DFG-Flip Process of c-Met Kinase Revealed by Metadynamics Simulations
Tao Jiang et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2022)
Crystal structure of 4-(((2-(3-(1-(3-(3-cyanophenyl)-6-oxopyridazin-1(6H)-yl)ethyl)phenyl) pyrimidin-5-yl)oxy)methyl)-1-methylpiperidin-1-ium chloride monohydrate, C30H33N6O2Cl
Han Yao et al.
ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES (2022)
Design, synthesis and biological evaluation of indole-based [1,2,4] triazolo[4,3-a] pyridine derivatives as novel microtubule polymerization inhibitors
Cheng-Jun Wu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFRL858R/T790M inhibitors
Jianheng Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
The twists and turns of chiral chemistry
Lewis E. MacKenzie et al.
NATURE CHEMISTRY (2021)
Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
Hang-Ping Yao et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
The Exploration of Chirality for Improved Druggability within the Human Kinome
Debasmita Saha et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Aberrant activation of hepatocyte growth factor/MET signaling promotes ?-catenin?mediated prostatic tumorigenesis
Joseph Aldahl et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
Haiyu Wang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Ravi Salgia et al.
CANCER TREATMENT REVIEWS (2020)
MET-dependent solid tumours - molecular diagnosis and targeted therapy
Robin Guo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity
Pei-Lu Song et al.
BIOORGANIC CHEMISTRY (2019)
HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers
Fatemeh Moosavi et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2019)
Safety and Tolerability of c-MET Inhibitors in Cancer
Alberto Puccini et al.
DRUG SAFETY (2019)
Learning Medicinal Chemistry Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Rules from Cross-Company Matched Molecular Pairs Analysis (MMPA)
Christian Kramer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
Mohamed Bouattour et al.
HEPATOLOGY (2018)
Apoptosis: A Target for Anticancer Therapy
Claire M. Pfeffer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Yazhuo Zhang et al.
MOLECULAR CANCER (2018)
In silico exploration of aryl sulfonamide analogs as voltage-gated sodium channel 1.7 inhibitors by using 3D-QSAR, molecular docking study, and molecular dynamics simulations
Mingxing Wang et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2018)
Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment
Agnieszka A. Rucki et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Conor A. Bradley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Hepatocyte growth factor/MET in cancer progression and biomarker discovery
Kunio Matsumoto et al.
CANCER SCIENCE (2017)
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity
Alessandro A. Boezio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
Dieter Dorsch et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Design and Optimization of a Series of 1-Sulfonylpyrazolo[4,3-b]pyridines as Selective c-Met Inhibitors
Yuchi Ma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Stereoselectivity of chiral drug transport: a focus on enantiomer-transporter interaction
Quan Zhou et al.
DRUG METABOLISM REVIEWS (2014)
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
Elizabeth C. Smyth et al.
ONCOTARGETS AND THERAPY (2014)
Progress in cancer therapy targeting c-Met signaling pathway
Kyung Hee Jung et al.
ARCHIVES OF PHARMACAL RESEARCH (2012)
Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
An efficient and promising method to prepare Ladostigil (TV3326) via asymmetric transfer hydrogenation catalyzed by Ru-Cs-DPEN in an HCOONa-H2O-surfactant system
Zonghua Luo et al.
TETRAHEDRON-ASYMMETRY (2012)
The Significance of Chirality in Drug Design and Development
W. H. Brooks et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Pharmacologically active compounds in the environment and their chirality
Barbara Kasprzyk-Hordern
CHEMICAL SOCIETY REVIEWS (2010)
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
Neru Munshi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
Fawn Qian et al.
CANCER RESEARCH (2009)
Showering c-MET-dependent cancers with drugs
Beatrice S. Knudsen et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The MET receptor tyrosine kinase in invasion and metastasis
Silvia Benvenuti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
JG Christensen et al.
CANCER LETTERS (2005)
Enantioselective pharmacokinetics of ibuprofen and involved mechanisms
HP Hao et al.
DRUG METABOLISM REVIEWS (2005)
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
G Maulik et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
分享论文
